Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 16/20 | 0.35 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.34 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.34 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA4 | P22748 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6462455 | 0.94 | PTGS2 (0.35) | PTGS2AKR1C3AKR1C2PTGS1HRH4 | |
| SCHEMBL6468452 | 0.93 | PTGS2 (0.36) | PTGS2AKR1C3AKR1C2PTGS1HRH4 | |
| SCHEMBL6462430 | 0.93 | PTGS2 (0.42) | PTGS2AKR1C3AKR1C2PTGS1HRH4 | |
| SCHEMBL6464802 | 0.92 | PTGS2 (0.36) | PTGS2AKR1C3AKR1C2PTGS1HRH4 | |
| SCHEMBL6460231 | 0.92 | PTGS2 (0.37) | PTGS2AKR1C3AKR1C2PTGS1 | |
| SCHEMBL6460340 | 0.91 | AKR1C3 (0.38) | PTGS2AKR1C3AKR1C2PTGS1 | |
| SCHEMBL6462135 | 0.90 | PTGS2 (0.39) | PTGS2AKR1C3AKR1C2PTGS1HRH4 | |
| SCHEMBL6465489 | 0.89 | PTGS2 (0.37) | PTGS2AKR1C3AKR1C2 | |
| SCHEMBL5800215 | 0.89 | PTGS2 (0.42) | PTGS2PTGS1HRH4 | |
| SCHEMBL6465593 | 0.89 | PTGS2 (0.47) | PTGS2AKR1C3AKR1C2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050032747-A1 | COX-2 and FAAH inhibitors | POLYMER CONCEPTS TECHNOLOGIES PBY, INC. | 2005-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050032747-A1 | COX-2 and FAAH inhibitors | FAAH2, FAAH, PTGS2 | PTGS2 3/4885AKR1C3 585/4885AKR1C2 342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.